1. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018-1023. 15390328.
2. Watkins PB, Seeff LB. Drug-induced liver injury: Summary of a single topic clinical research conference. Hepatology 2006;43:618-631. 16496329.
4. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 2007;6:673-684. 17967156.
5. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: Mechanisms and test systems. Hepatology 2001;33:1009-1013. 11283870.
7. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005;33:1-5. 15805049.
8. Vitug AC, Goldman JM. Hepatotoxicity from antithyroid drugs. Horm Res 1985;21:229-234. 4007783.
9. Cooper DS. The side effects of antithyroid drugs. The Endocrinologist 1999;9:457-478.
11. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med 2009;360:1574-1575. 19357418.
12. Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 1997;82:1727-1733. 9177371.
15. Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism: a cohort study. Ann Intern Med 1993;118:424-428. 8439116.
16. Kim HJ, Kim BH, Han YS, Yang I, Kim KJ, Dong SH, et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol 2001;96:165-169. 11197248.
17. Hanson JS. Propylthiouracil and hepatitis: two cases and a review of the literature. Arch Intern Med 1984;144:994-996. 6608933.
20. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-917. 15745981.
21. Mikhail NE. Methimazole-induced cholestatic jaundice. South Med J 2004;97:178-182. 14982270.
22. Arab DM, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1995;80:1083-1085. 7714072.
23. Schwab GP, Wetscher GJ, Vogl W, Redmond E. Methimazole-induced cholestatic liver injury, mimicking sclerosing cholangitis. Langenbecks Arch Chir 1996;381:225-227. 8817448.
24. Limaye A, Ruffolo PR. Propylthiouracil-induced fatal hepatic necrosis. Am J Gastroenterol 1987;82:152-154. 3812421.
25. Safani MM, Tatro DS, Rudd P. Fatal propylthiouracil-induced hepatitis. Arch Intern Med 1982;142:838-839. 7073426.
27. Gallelli L, Staltari O, Palleria C, De Sarro G, Ferraro M. Hepatotoxicity induced by methimazole in a previously healthy patient. Curr Drug Saf 2009;4:204-206. 19534646.
28. Hung YT, Yu WK, Chow E. Delayed cholestatic hepatitis due to methimazole. Hong Kong Med J 1999 6;5(2):200-201. 11821593.
30. Fan PW, Bolton JL. Bioactivation of tamoxifen to metabolite E quinone methide: reaction with glutathione and DNA. Drug Metab Dispos 2001;29:891-896. 11353759.
31. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR, Corcoran GB. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 1976;193:901-903. 7838.
33. Jewell H, Maggs JL, Harrison AC, O'Neill PM, Ruscoe JE, Park BK. Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica 1995;25:199-217. 7618347.
34. Heidari R, Babaei H, Eghbal MA. Amodiaquine-induced toxicity in isolated rat hepatocytes and the cytoprotective effects of taurine and/or N-acetyl cysteine. Res Pharm Sci 2014;9:97-105.
35. Lee PW, Neal RA. Metabolism of methimazole by rat liver cytochrome P-450-containing monoxygenases. Drug Metab Dispos 1978;6:591-600. 30610.
36. Mizutani T, Yoshida K, Murakami M, Shirai M, Kawazoe S. Evidence for the involvement of N-methylthiourea, a ring cleavage metabolite, in the hepatotoxicity of methimazole in glutathione-depleted mice: structure-toxicity and metabolic studies. Chem Res Toxicol 2000;13:170-176. 10725113.
37. Poulsen LL, Hyslop RM, Ziegler DM. S-oxidation of thioureylenes catalyzed by a microsomal flavoprotein mixed-function oxidase. Biochem Pharmacol 1974;23:3431-3440. 4441423.
38. Kedderis GL, Rickert DE. Loss of rat liver microsomal cytochrome P-450 during methimazole metabolism. Role of flavin-containing monooxygenase. Drug Metab Dispos 1985;13:58-61. 2858378.
39. Shangari N, O'Brien PJ. The cytotoxic mechanism of glyoxal involves oxidative stress. Biochem Pharmacol 2004;68:1433-1442. 15345333.
40. Mansuy D, Dansette PM. Sulfenic acids as reactive intermediates in xenobiotic metabolism. Arch Biochem Biophys 2011;507:174-185. 20869346.
41. Heidari R, Babaei H, Eghbal M. Mechanisms of methimazole cytotoxicity in isolated rat hepatocytes. Drug Chem Toxicol 2013;36:403-411. 23256569.
42. Lindsay RH, Cash AG, Vaughn AW, Hill JB. Glucuronide conjugation of 6-n-propyl-2-thiouracil and other antithyroid drugs by guinea pig liver microsomes in vitro. Biochem Pharmacol 1977;26:617-623. 16610.
44. Lam DC, Lindsay RH. Oxidation and binding of [2-(14)C]propylthiouracil in human polymorhonuclear leukocytes. Drug Metab Dispos 1979;7:285-289. 40767.
45. Balkin MS, Buchholtz M, Ortiz J, Green AJ. Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF). Thyroid 1993;3:305-309. 7509672.
46. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999;20:342-349. 10431214.
47. Miners JO, McKinnon RA, Mackenzie PI. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002;181:453-456. 12505351.
48. Taurog A, Dorris ML, Guziec LJ, Guziec FS Jr. The selenium analog of methimazole measurement of its inhibitory effect on type I 5'-deiodinase and of its antithyroid activity. Biochem Pharmacol 1994;48:1447-1453. 7524506.
50. Brittebo EB. Metabolism-Dependent Toxicity of Methimazole in the Olfactory Nasal Mucosa. Pharmacol Toxicol 1995;76:76-79. 7753763.
51. Mizutani T, Murakami M, Shirai M, Tanaka M, Nakanishi K. Metabolism-dependent hepatotoxicity of methimazole in mice depleted of glutathione. J Appl Toxicol 1999;19:193-198. 10362270.
52. Heidari R, Babaei H, Roshangar L, Eghbal MA. Effects of Enzyme Induction and/or Glutathione Depletion on Methimazole-Induced Hepatotoxicity in Mice and the Protective Role of N-Acetylcysteine. Adv Pharm Bull 2014;4:21-28. 24409405.
53. Bray TM, Taylor CG. Tissue glutathione, nutrition, and oxidative stress. Can J Physiol Pharmacol 1993;71:746-751. 8313240.
54. Shaw S, Rubin KP, Lieber CS. Depressed hepatic glutathione and increased diene conjugates in alcoholic liver disease. Evidence of lipid peroxidation. Dig Dis Sci 1983;28:585-589. 6861588.
55. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002;6:755-774. 12362579.
56. Kobayashi M, Higuchi S, Ide M, Nishikawa S, Fukami T, Nakajima M, et al. Th2 cytokine-mediated methimazole-induced acute liver injury in mice. J Appl Toxicol 2012;32:823-833. 22407903.
57. Diehl AM. Cytokine regulation of liver injury and repair. Immunol Rev 2000;174:160-171. 10807515.
58. Lacour S, Gautier JC, Pallardy M, Roberts R. Cytokines as potential biomarkers of liver toxicity. Cancer Biomark 2005;1:29-39. 17192030.
59. Thong HY, Chu CY, Chiu HC, others . Methimazole-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and lupus-like syndrome with a cutaneous feature of vesiculo-bullous systemic lupus erythematosus. Acta Derm Venereol 2002;82:206-208. 12353714.
60. Weiss M, Hassin D, Bank H. Propylthiouracil-induced hepatic damage. Arch Intern Med 1980;140:1184-1185. 6893265.
61. Hayashida CY, Duarte AJ, Sato AE, Yamashiro-Kanashiro EH. Neonatal hepatitis and lymphocyte sensitization by placental transfer of propylthiouracil. J Endocrinol Invest 1990;13:937-941. 2090674.
62. Maggiore G, Larizza D, Lorini R, De Giacomo C, Scotta MS, Severi F. Propylthiouracil hepatotoxicity mimicking autoimmune chronic active hepatitis in a girl. J Pediatr Gastroenterol Nutr 1989;8:547-548. 2723949.
63. Gunton JE, Stiel J, Caterson RJ, McElduff A. Clinical case seminar: Anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endocrinol Metab 1999;84:13-16. 9920055.
65. Sera N, Ashizawa K, Ando T, Abe Y, Ide A, Usa T, et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 2000;10:595-599. 10958312.
66. Uetrecht J. Immune-mediated adverse drug reactions. Chem Res Toxicol 2009;22:24-34. 19149477.
67. Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: reactive metabolites formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002;3:367-377. 12093356.
68. Ganey PE, Luyendyk JP, Maddox JF, Roth RA. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 2004;150:35-51. 15522260.
70. Fede G, Germani G, Gluud C, Gurusamy KS, Burroughs AK. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev 2011;(6):CD002800 doi:
10.1002/14651858. CD 002800.pub3. 21678335.
71. Tome S, Lucey MR. Review article: current management of alcoholic liver disease. Aliment Pharmacol Ther 2004;19:707-714. 15043511.
72. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, et al. Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice. Gastroenterology 1999;117:942-952. 10500078.
74. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002;22:145-155. 12016546.
75. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-499. 15931258.
76. Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC, Romero-Gomez M, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. Hepatology 2009;49:2001-2009. 19475693.
77. Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 1997;82:1727-1733. 9177371.
81. Jonas MM, Eidson MS. Propylthiouracil hepatotoxicity: two pediatric cases and review of the literature. J Pediatr Gastroenterol Nutr 1988;7:776-779. 3054039.
83. Boelsterli UA, Lim PL. Mitochondrial abnormalities--a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol 2007;220:92-107. 17275868.
84. Mete UÖ, Kaya M, Çolakoglu S, Polat S, Tap Ö, ÖZbilgin MK, et al. Ultra-structure of the liver in propylthiouracil induced hepatitis. J Isl Acad Sci 1993;6:268-276.
85. Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005;1:447-471. 16863455.
86. Ginsberg G, Hattis D, Sonawane B. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol Appl Pharmacol 2004;198:164-183. 15236952.
87. Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, et al. Agranulocytosis associated with antithyroid drugs: effects of patient age and drug dose. Ann Intern Med 1983;98:26-29. 6687345.
88. Ramos-Bonner LS, Goldberg TH, Moyer S, Anastasopoulou C. Methimazole-induced cholestatic jaundice in an elderly hyperthyroid patient. Am J Geriatr Pharmacother 2007;5:236-240. 17996663.
91. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489-499. 11836274.
92. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2001;2:777-780. 11526384.
93. Weetman AP. Graves' disease. N Engl J Med 2000;343:1236-1248. 11071676.
94. Seven A, Seymen O, Hatemi S, Hatemi H, Yiğit G, Candan G. Anti-oxidant status in experimental hyperthyrodism: effect of vitamin E supplementation. Clin Chim Acta 1996;256:65-74. 8960788.
95. Komosinska-Vassev K, Olczyk K, Kucharz EJ, Marcisz C, Winsz-Szczotka K, Kotulska A. Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves' disease during therapy. Clin Chim Acta 2000;300:107-117. 10958867.
96. Venditti P, Balestrieri M, Di Meo S, De Leo T. Effect of thyroid state on lipid peroxidation, antioxidant defences, and susceptibility to oxidative stress in rat tissues. J Endocrinol 1997;155:151-157. 9390017.
97. Venditti P, Di Meo S. Thyroid hormone-induced oxidative stress. Cell Mol Life Sci 2006;63:414-434. 16389448.
98. Levy M. Propylthiouracil hepatotoxicity. A review and case presentation. Clin Pediatr (Phila) 1993;32:25-29. 8419095.
99. Yang J, Zhong J, Zhou LZ, Hong T, Xiao XH, Wen GB. Sudden onset agranulocytosis and hepatotoxicity after taking methimazole. Intern Med 2012;51:2189-2192. 22892501.
100. Vilchez FJ, Torres I, Garcia-Valero A, Lopez-Tinoco C, de Los Santos A, Aguilar-Diosdado M. Concomitant agranulocytosis and hepatotoxicity after treatment with carbimazole. Ann Pharmacother 2006;40:2059-2063. 17077174.
101. Becker CE, Gorden P, Robbins J. Hepatitis from methimazole during adrenal steroid therapy for malignant exophthalmos. JAMA 1968;206:1787-1789. 4177058.
102. Lee SO, Choi JK, Kim HS, Seo JS, Ahn DS. A case of similar pattern of hepatotoxicity after propylthiouracil and methimazole. Korean J Hepatol 1999;5:136-141.
103. Heidari R, Babaei H, Eghbal MA. Cytoprotective effects of organosulfur compounds against methimazole-induced toxicity in isolated rat hepatocytes. Adv Pharm Bull 2013;3:135-142. 24312826.
105. Roy G, Bhabak KP, Mugesh G. Interactions of antithyroid drugs and their analogues with halogens and their biological implications. Cryst Growth Des 2011;11:2279-2286.
106. Manna D, Roy G, Mugesh G. Antithyroid drugs and their analogues: synthesis, structure, and mechanism of action. Acc Chem Res 2013;46:2706-2715. 23883148.
107. Roy G, Mugesh G. Anti-thyroid drugs and thyroid hormone synthesis: effect of methimazole derivatives on peroxidase-catalyzed reactions. J Am Chem Soc 2005;127:15207-15217. 16248663.